Prospective clinical trials have shown that 14% of patients with breast cancer had their therapeutic regimen modified as a result of changes in the HR/HER2 status in primary tumor tissues or metastatic cancerous tissue despite endocrine treatment before biopsy [10]. This evidence concerns the gene ERBB2 and breast carcinoma.